CAM
STSA

ClariVest Asset Management’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

ClariVest Asset Management’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-612
Closed -$3K – 835
2021
Q3 		$3K Buy
+612
New +$3.24K ﹤0.01% 612

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClariVest Asset Management's STSA Position: Q4 2021 in Review

ClariVest Asset Management sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2021, closing a stake of 612 shares — an estimated $3K sold.

ClariVest Asset Management first reported a position in STSA in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 35 funds tracked by Wall St. Rank hold STSA as of Q4 2021.

  • ClariVest Asset Management reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 612 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $3K.
  • ClariVest Asset Management first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • ClariVest Asset Management's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $3K in Q3 2021.
  • 35 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on ClariVest Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.